The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

INTRODUCTION: Activation of the PI3K/AKT pathway is a common phenomenon in cancer due to multiple mechanisms, including mutation of PI3KCA, loss or mutation of PTEN, or over-expression of receptor tyrosine kinases. We recently developed a novel AKT kinase inhibitor, AZD5363, and demonstrated that HG...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Davies, Barry R, Han, Sufang, Zhou, Minhua, Bai, Yu, Zhang, Jingchuan, Xu, Yan, Tang, Lily, Wang, Huiying, Liu, Yuan Jie, Yin, Xiaolu, Ji, Qunsheng, Yu, De-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850695/
https://www.ncbi.nlm.nih.gov/pubmed/24088382
http://dx.doi.org/10.1186/1479-5876-11-241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850695/
https://www.ncbi.nlm.nih.gov/pubmed/24088382
http://dx.doi.org/10.1186/1479-5876-11-241

Ejemplares similares